These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37969049)

  • 1. Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
    Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Idehara K; Nitta D
    ESC Heart Fail; 2024 Feb; 11(1):261-270. PubMed ID: 37969049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial.
    Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Reifsnider OS; Rakonczai P; Stargardter M; Murata T; Hirase T; Nitta D
    J Cardiol; 2023 Jun; 81(6):522-530. PubMed ID: 36858174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction.
    Tafazzoli A; Reifsnider OS; Bellanca L; Ishak J; Carrasco M; Rakonczai P; Stargardter M; Linden S
    Eur J Health Econ; 2023 Dec; 24(9):1441-1454. PubMed ID: 36463524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40.
    Kolovos S; Bellanca L; Groyer H; Rosano GMC; Solé A; Gaultney J; Linden S
    ESC Heart Fail; 2023 Dec; 10(6):3385-3397. PubMed ID: 37670496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.
    Zheng J; Parizo JT; Spertus JA; Heidenreich PA; Sandhu AT
    JAMA Intern Med; 2022 Dec; 182(12):1278-1288. PubMed ID: 36342696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE
    Fauchier L; Lamblin N; Tardu J; Bellier L; Groyer H; Ittah D; Chollet J; Linden S; Levy P
    Pharmacoecon Open; 2024 Jan; 8(1):19-30. PubMed ID: 37606866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
    Krittayaphong R; Permsuwan U
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):577-590. PubMed ID: 35796952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.
    Tang Y; Sang H
    Front Pharmacol; 2022; 13():1030642. PubMed ID: 36386229
    [No Abstract]   [Full Text] [Related]  

  • 9. A cost-effectiveness analysis of empagliflozin for heart failure patients across the full spectrum of ejection fraction in Spain: combined results of the EMPEROR-Preserved and EMPEROR-Reduced trials.
    García-Moll X; Croci F; Solé A; Hartgers-Gubbels ES; Calleja-Hernández MA
    Expert Rev Cardiovasc Ther; 2024; 22(1-3):131-139. PubMed ID: 38416135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China.
    Lou Y; Hu T; Huang J
    Am J Cardiovasc Drugs; 2023 Jan; 23(1):47-57. PubMed ID: 36207658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction.
    Tan YJ; Linden S; Ong SC
    PLoS One; 2024; 19(8):e0305257. PubMed ID: 39178204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
    JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.
    Reifsnider OS; Tafazzoli A; Linden S; Ishak J; Rakonczai P; Stargardter M; Kuti E
    J Am Heart Assoc; 2024 Feb; 13(4):e029042. PubMed ID: 38362909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
    Zhou J; Liew D; Kaye DM; Zoungas S; Stub D
    Circ Cardiovasc Qual Outcomes; 2022 Oct; 15(10):e008638. PubMed ID: 36252135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data.
    Davis JA; Booth D; McEwan P; Solomon SD; McMurray JJV; de Boer RA; Comin-Colet J; Bachus E; Chen J
    Eur J Heart Fail; 2024 Mar; 26(3):664-673. PubMed ID: 38509642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia.
    Ong SC; Low JZ; Linden S
    Front Pharmacol; 2023; 14():1195124. PubMed ID: 37342587
    [No Abstract]   [Full Text] [Related]  

  • 17. Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial.
    Sattar N; Butler J; Lee MMY; Harrington J; Sharma A; Zannad F; Filippatos G; Verma S; Januzzi JL; Ferreira JP; Pocock SJ; Pfarr E; Ofstad AP; Brueckmann M; Packer M; Anker SD
    Eur J Heart Fail; 2024 Apr; 26(4):900-909. PubMed ID: 38558521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis.
    Rane A; Nechi RN; Imam M; Zoni CR; Ndikumukiza C; Karaye IM; Yunusa I; Alanzi A
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1045-1053. PubMed ID: 37610112
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.
    Coats AJS; Butler J; Tsutsui H; Doehner W; Filippatos G; Ferreira JP; Böhm M; Chopra VK; Verma S; Nordaby M; Iwata T; Nitta D; Ponikowski P; Zannad F; Packer M; Anker SD
    J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):412-424. PubMed ID: 38158636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
    Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
    Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.